vs
FONAR CORP（FONR）与LivaNova PLC（LIVN）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是FONAR CORP的14.1倍（$360.9M vs $25.5M）。LivaNova PLC净利率更高（8.6% vs 8.0%，领先0.5%）。LivaNova PLC同比增速更快（12.1% vs 2.4%）。LivaNova PLC自由现金流更多（$50.2M vs $-227.0K）。过去两年LivaNova PLC的营收复合增速更高（10.6% vs -0.3%）
FONAR是一家专业医疗技术企业，专注于设计、制造及销售包括立式、开放式在内的创新磁共振成像（MRI）设备，主要服务美国的医院、影像诊断中心及医疗机构，为临床诊断提供高精度扫描解决方案。
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
FONR vs LIVN — 直观对比
营收规模更大
LIVN
是对方的14.1倍
$25.5M
营收增速更快
LIVN
高出9.8%
2.4%
净利率更高
LIVN
高出0.5%
8.0%
自由现金流更多
LIVN
多$50.4M
$-227.0K
两年增速更快
LIVN
近两年复合增速
-0.3%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $25.5M | $360.9M |
| 净利润 | $2.1M | $30.9M |
| 毛利率 | — | 65.2% |
| 营业利润率 | 13.5% | 11.8% |
| 净利率 | 8.0% | 8.6% |
| 营收同比 | 2.4% | 12.1% |
| 净利润同比 | 4.7% | -44.7% |
| 每股收益（稀释后） | — | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FONRLIVN
| Q4 25 | $25.5M | $360.9M | ||
| Q3 25 | $26.0M | $357.8M | ||
| Q2 25 | $27.3M | $352.5M | ||
| Q1 25 | $27.2M | $316.9M | ||
| Q4 24 | $24.9M | $321.8M | ||
| Q3 24 | $25.0M | $318.1M | ||
| Q2 24 | $25.9M | $318.6M | ||
| Q1 24 | $25.7M | $294.9M |
净利润FONRLIVN
| Q4 25 | $2.1M | $30.9M | ||
| Q3 25 | $2.3M | $26.8M | ||
| Q2 25 | $729.3K | $27.2M | ||
| Q1 25 | $2.5M | $-327.3M | ||
| Q4 24 | $2.0M | $55.9M | ||
| Q3 24 | $3.1M | $33.0M | ||
| Q2 24 | $830.4K | $16.3M | ||
| Q1 24 | $1.9M | $-41.9M |
毛利率FONRLIVN
| Q4 25 | — | 65.2% | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 69.7% | ||
| Q4 24 | — | 68.2% | ||
| Q3 24 | — | 70.8% | ||
| Q2 24 | — | 68.7% | ||
| Q1 24 | — | 70.3% |
营业利润率FONRLIVN
| Q4 25 | 13.5% | 11.8% | ||
| Q3 25 | 14.1% | 15.1% | ||
| Q2 25 | 5.3% | 15.4% | ||
| Q1 25 | 15.2% | 15.3% | ||
| Q4 24 | 11.9% | 11.5% | ||
| Q3 24 | 21.0% | 11.2% | ||
| Q2 24 | 7.4% | 12.6% | ||
| Q1 24 | 16.8% | 5.5% |
净利率FONRLIVN
| Q4 25 | 8.0% | 8.6% | ||
| Q3 25 | 8.7% | 7.5% | ||
| Q2 25 | 2.7% | 7.7% | ||
| Q1 25 | 9.2% | -103.3% | ||
| Q4 24 | 7.9% | 17.4% | ||
| Q3 24 | 12.6% | 10.4% | ||
| Q2 24 | 3.2% | 5.1% | ||
| Q1 24 | 7.3% | -14.2% |
每股收益（稀释后）FONRLIVN
| Q4 25 | — | $0.57 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | — | $0.50 | ||
| Q1 25 | — | $-6.01 | ||
| Q4 24 | — | $1.04 | ||
| Q3 24 | — | $0.60 | ||
| Q2 24 | — | $0.30 | ||
| Q1 24 | — | $-0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $121.0K | $635.6M |
| 总债务越低越好 | — | $376.1M |
| 股东权益账面价值 | $176.9M | $1.2B |
| 总资产 | $217.2M | $2.6B |
| 负债/权益比越低杠杆越低 | — | 0.31× |
8季度趋势，按日历期对齐
现金及短期投资FONRLIVN
| Q4 25 | $121.0K | $635.6M | ||
| Q3 25 | $122.0K | $646.1M | ||
| Q2 25 | $56.5M | $593.6M | ||
| Q1 25 | $123.0K | $738.4M | ||
| Q4 24 | $121.0K | $428.9M | ||
| Q3 24 | $136.0K | $346.4M | ||
| Q2 24 | $56.5M | $329.2M | ||
| Q1 24 | $134.0K | $309.2M |
总债务FONRLIVN
| Q4 25 | — | $376.1M | ||
| Q3 25 | — | $434.5M | ||
| Q2 25 | — | $430.6M | ||
| Q1 25 | — | $628.2M | ||
| Q4 24 | — | $627.0M | ||
| Q3 24 | — | $625.5M | ||
| Q2 24 | $66.9K | $624.5M | ||
| Q1 24 | — | $623.8M |
股东权益FONRLIVN
| Q4 25 | $176.9M | $1.2B | ||
| Q3 25 | $174.9M | $1.2B | ||
| Q2 25 | $172.6M | $1.1B | ||
| Q1 25 | $171.9M | $1.0B | ||
| Q4 24 | $169.8M | $1.3B | ||
| Q3 24 | $168.7M | $1.3B | ||
| Q2 24 | $166.0M | $1.2B | ||
| Q1 24 | $165.8M | $1.2B |
总资产FONRLIVN
| Q4 25 | $217.2M | $2.6B | ||
| Q3 25 | $218.4M | $2.6B | ||
| Q2 25 | $216.9M | $2.5B | ||
| Q1 25 | $214.9M | $2.6B | ||
| Q4 24 | $208.0M | $2.5B | ||
| Q3 24 | $212.3M | $2.5B | ||
| Q2 24 | $214.2M | $2.5B | ||
| Q1 24 | $209.6M | $2.5B |
负债/权益比FONRLIVN
| Q4 25 | — | 0.31× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.61× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | 0.00× | 0.50× | ||
| Q1 24 | — | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $171.0K | $82.4M |
| 自由现金流经营现金流 - 资本支出 | $-227.0K | $50.2M |
| 自由现金流率自由现金流/营收 | -0.9% | 13.9% |
| 资本支出强度资本支出/营收 | 1.6% | 8.9% |
| 现金转化率经营现金流/净利润 | 0.08× | 2.67× |
| 过去12个月自由现金流最近4个季度 | $5.7M | $173.3M |
8季度趋势，按日历期对齐
经营现金流FONRLIVN
| Q4 25 | $171.0K | $82.4M | ||
| Q3 25 | $1.7M | $85.1M | ||
| Q2 25 | $4.2M | $62.9M | ||
| Q1 25 | $3.1M | $24.0M | ||
| Q4 24 | $2.2M | $78.7M | ||
| Q3 24 | $1.7M | $51.0M | ||
| Q2 24 | $4.6M | $43.4M | ||
| Q1 24 | $2.8M | $10.0M |
自由现金流FONRLIVN
| Q4 25 | $-227.0K | $50.2M | ||
| Q3 25 | $-177.0K | $62.2M | ||
| Q2 25 | $3.6M | $47.8M | ||
| Q1 25 | $2.6M | $13.2M | ||
| Q4 24 | $1.5M | $68.3M | ||
| Q3 24 | $-148.0K | $32.8M | ||
| Q2 24 | $4.2M | $31.2M | ||
| Q1 24 | $2.6M | $3.6M |
自由现金流率FONRLIVN
| Q4 25 | -0.9% | 13.9% | ||
| Q3 25 | -0.7% | 17.4% | ||
| Q2 25 | 13.1% | 13.6% | ||
| Q1 25 | 9.4% | 4.2% | ||
| Q4 24 | 6.0% | 21.2% | ||
| Q3 24 | -0.6% | 10.3% | ||
| Q2 24 | 16.1% | 9.8% | ||
| Q1 24 | 10.2% | 1.2% |
资本支出强度FONRLIVN
| Q4 25 | 1.6% | 8.9% | ||
| Q3 25 | 7.2% | 6.4% | ||
| Q2 25 | 2.4% | 4.3% | ||
| Q1 25 | 2.2% | 3.4% | ||
| Q4 24 | 3.0% | 3.2% | ||
| Q3 24 | 7.2% | 5.7% | ||
| Q2 24 | 1.6% | 3.8% | ||
| Q1 24 | 0.7% | 2.2% |
现金转化率FONRLIVN
| Q4 25 | 0.08× | 2.67× | ||
| Q3 25 | 0.75× | 3.18× | ||
| Q2 25 | 5.79× | 2.32× | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | 1.14× | 1.41× | ||
| Q3 24 | 0.53× | 1.55× | ||
| Q2 24 | 5.54× | 2.65× | ||
| Q1 24 | 1.50× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
